Table 1.

Recent trials on convalescent plasma from United States

NCT	Study title	Study characteristics	Conducting authority
NCT04342195	Acquiring convalescent specimens to isolate and identify potent monoclonal antibodies against COVID‐19	Observational, cross‐sectional, 12 participants	Columbia University
NCT04338360	Expanded access to convalescent plasma for the treatment of patients with COVID‐19	Expanded access	Mayo Clinic (all centers of US)
NCT04340050	Pilot study for use of convalescent plasma collected from patients recovered from COVID‐19 disease for transfusion as an empiric treatment during the 2020 pandemic at the University of Chicago Medical Center	Interventional (Clinical Trial), Single Group Assignment, 10 participants	University of Chicago, Chicago, Illinois,
NCT04343755	Phase IIa study exploring the safety and efficacy of convalescent plasma from recovered COVID‐19 donors collected by plasmapheresis as treatment for hospitalized subjects with COVID‐19 infection	Interventional (Clinical Trial), Single Group Assignment, 55 participants	Hackensack Meridian Health, New Jersey, United States,
NCT04344015	The goal of this study is to identify individuals who have previously been infected with COVID‐19 and collect plasma from those who meet inclusion criteria for convalescent plasma donation	Interventional (Clinical Trial), Single Group Assignment, 2000 participants	Thomas Jefferson University Hospital,
			Philadelphia, Pennsylvania,
NCT04343261	Convalescent plasma in the treatment of COVID 19	Interventional (Clinical Trial), Single Group Assignment, 15 participants	Trinity Health of New England, Hartford, Connecticut
NCT04344535	A randomized trial comparing the efficacy and safety of high‐titer anti‐SARS‐CoV‐2 plasma vs standard plasma in hospitalized patients with COVID‐ 19 infection	Interventional (Clinical Trial), Parallel Assignment, 500 participants	Elliott Bennett‐Guerrero, Stony Brook University